Noscapine for the treatment of non-productive cough;Noscapin zur therapie des reizhustens

Atemwegs- und Lungenkrankheiten

Volumn 34, Issue 5, 2008, Pages 163-173

  Steinkamp, Gratiana ^a,c   Lindemann, H ^b  

^a Klinische Forschung   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c NONE   (Germany)

Author keywords

Antitussive agents; Non productive cough; Noscapine; Opioids

Indexed keywords

ANTITUSSIVE AGENT; CAPSAICIN; CAPTOPRIL; CLOBUTINOL; CODEINE; DEXTROMETHORPHAN; DIHYDROCODEINE; HYDROCODONE; NEOTUSSAN; NOSCAPINE; OPIATE; OPTIPECT; PAPAVERINE; PENTOXYVERINE; PLACEBO;

ACUTE DISEASE; ADDICTION; ALLERGY; ANAPHYLAXIS; CHILD CARE; CHRONIC DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; EUPHORIA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GERMANY; HUMAN; MENTAL DISEASE; MIOSIS; NEUROLOGIC DISEASE; PATHOGENESIS; PRESCRIPTION; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SLEEP PATTERN; SOMNOLENCE; SYNCOPE; TINNITUS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UROGENITAL TRACT DISEASE; URTICARIA;

EID: 47049092763     PISSN: 03413055     EISSN: None     Source Type: Journal    
DOI: 10.5414/atp34163     Document Type: Review

References (43)

1. Leitlinie Husten der Gesellschaft für Pädiatrische Pneumologie. AWMF Leitlinien-Register Nr. 026/005. 1998.
2. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte). Codein-haltige Arzneimittel: Anwendung in der Stillzeit. 2007; 7-9.
3. Bickerman HA, Barach AL. The experimental production of cough in human subjects induced by citric acid aerosols: preliminary studies on the evaluation of antitussive agents. Am J Med Sci. 1954; 228: 156-163.
4. Bickerman HA, German E, Cohen BM, Itkin SE. The cough response of healthy human subjects stimulated by citric acid aerosol. II. Evaluation of antitussive agents. Am J Med Sci. 1957; 234: 191-206.
5. Bundesinstitut für Risikobewertung. Noscapin. Gesundheitliche Bewertung Nr. 012/2006 des BfR vom 27. Dezember 2005; 2006: 26-27.
6. Cario W. Noscapinsaft bei kleinen Kindern. TE Pädiatrie. 1997; 10: 563-568.
7. Chollet DF, Ruols C, Arnera V. Determination of noscapine in human plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997; 701: 81-85.
8. Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001; 108: 776-789.
9. Dahlstrom B, Mellstrand T, Lofdahl CG, Johansson M. Pharmacokinetic properties of noscapine. Eur J Clin Pharmacol. 1982; 22: 535-539.
10. Ebrahimi SA, Zareie MR, Rostami P, Mahmoudian M. Interaction of noscapine with the bradykinin mediation of the cough response. Acta Physiol Hung. 2003; 90: 147-155.
11. Ellison E. A long-acting antitussive preparation. General Practitioner. 2007; 188: 249-252.
12. Fritz M, Strohe A. Experiences with a new cough blocking agent with immediate and prolonged effect. Med Monatsschr. 1971; 25: 37-39.
13. Gatehouse DG, Stemp G, Pascoe S, Wilcox P, Hawker J, Tweats DJ. Investigations into the induction of aneuploidy and polyploidy in mammalian cells by the anti-tussive agent noscapine hydrochloride. Mutagenesis. 1991; 6: 279-283.
14. Gillissen A, Tasci S, Ewig S, Schäfer H, Zielen S. Sinn und Unsinn von Antitussiva. Internist. 2001; 42: 134-142.
15. Günthner W. Die Bronchitis und ihre Behandlung mit Capval®. Therapiewoche. 1977; 27: 356-358.
16. Imhof E, Russi E, Perruchoud AP. Pharmacotherapy of cough. Schweiz Med Wochenschr. 1988; 118: 1067-1072.
17. Janschulte B. Erfahrungen mit Narcompren, einem neuen Hustenmittel. Med Klin (Munich). 1955; 50: 1788-1789.
18. Kamei J, Iwamoto Y, Misawa M, Kasuya Y. Effects of rimcazole, a specific antagonist of sigma sites, on the antitussive effects of non-narcotic antitussive drugs. Eur J Pharmacol. 1993; 242: 209-211.
19. Kardos P, Cegla U, Gillissen A, Kirsten D, Mitfessel H, Morr H et al. Guideline of the German respiratory society for diagnosis and treatment of patients suffering from acute or chronic cough. Pneumologie. 2004; 58: 570-602.
20. Karlsson JA, Lanner AS, Persson CG. Airway opioid receptors mediate inhibition of cough and reflex bronchoconstriction in guinea pigs. J Pharmacol Exp Ther. 1990; 252: 863-868.
21. Karlsson MO, Dahlstrom B, Eckernas SA, Johansson M, Alm AT. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol. 1990; 39: 275-279.
22. Karlsson MO, Dahlstrom B, Neil A. Characterization of high-affinity binding sites for the antitussive [3H]noscapine in guinea pig brain tissue. Eur J Pharmacol. 1988; 145: 195-203.
23. Ke Y, Ye K, Grossniklaus HE, Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother. 2000; 49: 217-225.
24. La BJ, PLisnier H. The antitussive and bronchodilating properties of narcotine hydrochloride. Arch Int Pharmacodyn Ther. 1995; 119: 205-213.
25. Läer S. Dextromethorphan - ein harmloses Hustenmittel? Deutsche Apothekerzeitung. 2007; 147: 42-47.
26. Lindemann H. Das hustende Kind. Atemw.- Lungenkrkh. 1995; 21: 228-234.
27. Lader RE. Safe reduction of the cough reflex with noscapine. A preliminary communication on a new use for an old drug. Anaesthesia. 1969; 24: 355-358.
28. Mahmoudian M, Mojaverian N. Efffect of noscapine, the antitussive opioid alkaloid, on bradykinin-induced smooth muscle contraction in the isolated ileum of the guinea-pig. Acta Physiol Hung. 2001; 88: 231-237.
29. Matthys H, Erhardt J, Ruhle KH. Objectivation of the effect of antitussive agents using tussometry in patients with chronic cough. Schweiz Med Wochenschr. 1985; 115: 307-311.
30. Mooraki A, Jenabi A, Jabbari M, Zolfaghari MI, Javanmardi SZ, Mahmoudian M et al. Noscapine suppresses angiotensin-converting enzyme inhibitors-induced cough. Nephrology (Carlton). 2005; 10: 348-350.
31. Morice AH, Fontana GA, Sovijarvi AR, Pistolesi M, Chung KF, Widdicombe J et al. The diagnosis and management of chronic cough. Eur Respir J. 2004; 24: 481-492.
32. Morice AH, Geppetti P. Cough; 5: The Type 1 vanilloid receptor: a sensory receptor for cough. Thorax. 2004; 59: 257-258.
33. Ohlsson S, Holm L, Myrberg O, Sundstrom A, Yue QY. Noscapine may increase the effect of warfarin. Br J Clin Pharmacol. 2008; 65: 277-278.
34. Olsson B, Bolme P, Dahlstrom B, Marcus C. Excretion of noscapine in human breast milk. Eur J Clin Pharmacol. 1986; 30: 213-215 (1986).
35. Ota Y, Endo N, Hirasawa M. Antitussive activity of narcotine derivatives. Chem Pharm Bull (Tokyo). 1964; 12: 569-578.
36. Peeters E. Les propriétés antitussives de la Noscapin. Scalpel. 1961; 42: 945-954.
37. Renovanz HD, Heissler K, Funk G. Tussometry: III. Tussometry in diagnosis. Wien Med Wochenschr. 1979; Suppl 58: 14-18.
38. Rett A. Zum Leitsymptom "Husten" und seiner Behandlung. Schweiz Rundschau Med. 61: 1967; 715-718.
39. Segal MS, Goldstein MM, Attinger EO. The use of noscapine (narcotine) as an antitussive agent. Dis Chest. 1957; 32: 305-309.
40. Seidenberg J. Husten im Kindesalter. Monatssehr Kinderheilkd. 1993; 141: 893-906.
41. Sukhinina GP. Pharmacological properties of noscapine. Farmakol Toksikol. 1968; 31: 702-705.
42. Teschler H. Pathophysiologie des Hustens. Vortrag; Frühjahrstagung der Rheinisch-westfälischen Vereinigung für Lungen-und Bronchialheilkunde 2002. http://www.rwv-lunge.de/dokumente/ fruehjahr2002/teschler.pdf
43. Tiveron C, Hartley-Asp B, Johansson CJ, Pacchierotti F. Noscapine does not show aneugenic activity in mouse oocytes. Mutagenesis. 1993; 8: 311-315.